Global Medical Sevofluran Market research
Global Medical Sevofluran Market research

Medical Sevofluran Comprehensive Study by Type (Generic Drug, Original Drug), Patient type (Children, Adults), Concentrations (5% sevoflurane (Adults), 7% sevoflurane (children), Others) Players and Region - Global Market Outlook to 2026

Medical Sevofluran Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 223 Pages 166 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Medical Sevofluran Market?

Sevoflurane refers to the type of medicines known as general anaesthetics, used to cause general anaesthesia before and during surgery. Although sevoflurane can be used by itself, combinations of anaesthetics are often used together. This helps produce more effective anaesthesia in some patients. It is an inhaled anaesthetic that is often used to put children asleep for surgery. During the process of waking up from the medication, it has been known to cause agitation and delirium.

The market study is being classified by Type (Generic Drug and Original Drug) and major geographies with country level break-up.

Abbott Laboratories (United States), Maruishi Pharmaceutical (Japan), Collins Ltd (Taiwan), Shenzhen Mindray Bio-Medical Electronics (China), Mylan Seiyaku (Japan), Baxter (United States), Jinan MingRui (China) and Hikma (United Kingdom) are some of the key players profiled in the study.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Medical Sevofluran market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Medical Sevofluran market by Type, Application and Region.

On the basis of geography, the market of Medical Sevofluran has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • The rise in the number of surgeries
  • Increasing Paediatric population
  • Rising number of emergency surgeries

Market Trend
  • Increasing research and development activities

Restraints
  • The adverse effect of the medical Sevofluran include drowsiness and dizziness

Opportunities
  • Increasing adoption of the medical sevoflurane owing to the rapid emergence from anaesthesia is generally seen with sevoflurane so early relief of postoperative pain may be required

Challenges
  • Availability of the alternative such as isoflurane





Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Medical Sevofluran Manufacturer, Government Regulatory and Research Organizations and End-Use Industry

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Generic Drug
  • Original Drug
By Patient type
  • Children
  • Adults

By Concentrations
  • 5% sevoflurane (Adults)
  • 7% sevoflurane (children)
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The rise in the number of surgeries
      • 3.2.2. Increasing Paediatric population
      • 3.2.3. Rising number of emergency surgeries
    • 3.3. Market Challenges
      • 3.3.1. Availability of the alternative such as isoflurane
    • 3.4. Market Trends
      • 3.4.1. Increasing research and development activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Medical Sevofluran, by Type, Patient type, Concentrations and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Medical Sevofluran (Value)
      • 5.2.1. Global Medical Sevofluran by: Type (Value)
        • 5.2.1.1. Generic Drug
        • 5.2.1.2. Original Drug
      • 5.2.2. Global Medical Sevofluran by: Patient type (Value)
        • 5.2.2.1. Children
        • 5.2.2.2. Adults
      • 5.2.3. Global Medical Sevofluran by: Concentrations (Value)
        • 5.2.3.1. 5% sevoflurane (Adults)
        • 5.2.3.2. 7% sevoflurane (children)
        • 5.2.3.3. Others
      • 5.2.4. Global Medical Sevofluran Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Medical Sevofluran (Volume)
      • 5.3.1. Global Medical Sevofluran by: Type (Volume)
        • 5.3.1.1. Generic Drug
        • 5.3.1.2. Original Drug
      • 5.3.2. Global Medical Sevofluran by: Patient type (Volume)
        • 5.3.2.1. Children
        • 5.3.2.2. Adults
      • 5.3.3. Global Medical Sevofluran by: Concentrations (Volume)
        • 5.3.3.1. 5% sevoflurane (Adults)
        • 5.3.3.2. 7% sevoflurane (children)
        • 5.3.3.3. Others
      • 5.3.4. Global Medical Sevofluran Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Medical Sevofluran (Price)
      • 5.4.1. Global Medical Sevofluran by: Type (Price)
  • 6. Medical Sevofluran: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Maruishi Pharmaceutical (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Collins Ltd (Taiwan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Shenzhen Mindray Bio-Medical Electronics (China)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mylan Seiyaku (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Baxter (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Jinan MingRui (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hikma (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Medical Sevofluran Sale, by Type, Patient type, Concentrations and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Medical Sevofluran (Value)
      • 7.2.1. Global Medical Sevofluran by: Type (Value)
        • 7.2.1.1. Generic Drug
        • 7.2.1.2. Original Drug
      • 7.2.2. Global Medical Sevofluran by: Patient type (Value)
        • 7.2.2.1. Children
        • 7.2.2.2. Adults
      • 7.2.3. Global Medical Sevofluran by: Concentrations (Value)
        • 7.2.3.1. 5% sevoflurane (Adults)
        • 7.2.3.2. 7% sevoflurane (children)
        • 7.2.3.3. Others
      • 7.2.4. Global Medical Sevofluran Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Medical Sevofluran (Volume)
      • 7.3.1. Global Medical Sevofluran by: Type (Volume)
        • 7.3.1.1. Generic Drug
        • 7.3.1.2. Original Drug
      • 7.3.2. Global Medical Sevofluran by: Patient type (Volume)
        • 7.3.2.1. Children
        • 7.3.2.2. Adults
      • 7.3.3. Global Medical Sevofluran by: Concentrations (Volume)
        • 7.3.3.1. 5% sevoflurane (Adults)
        • 7.3.3.2. 7% sevoflurane (children)
        • 7.3.3.3. Others
      • 7.3.4. Global Medical Sevofluran Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Medical Sevofluran (Price)
      • 7.4.1. Global Medical Sevofluran by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Medical Sevofluran: by Type(USD Million)
  • Table 2. Medical Sevofluran Generic Drug , by Region USD Million (2015-2020)
  • Table 3. Medical Sevofluran Original Drug , by Region USD Million (2015-2020)
  • Table 4. Medical Sevofluran: by Patient type(USD Million)
  • Table 5. Medical Sevofluran Children , by Region USD Million (2015-2020)
  • Table 6. Medical Sevofluran Adults , by Region USD Million (2015-2020)
  • Table 7. Medical Sevofluran: by Concentrations(USD Million)
  • Table 8. Medical Sevofluran 5% sevoflurane (Adults) , by Region USD Million (2015-2020)
  • Table 9. Medical Sevofluran 7% sevoflurane (children) , by Region USD Million (2015-2020)
  • Table 10. Medical Sevofluran Others , by Region USD Million (2015-2020)
  • Table 11. South America Medical Sevofluran, by Country USD Million (2015-2020)
  • Table 12. South America Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 13. South America Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 14. South America Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 15. Brazil Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 16. Brazil Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 17. Brazil Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 18. Argentina Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 19. Argentina Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 20. Argentina Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 21. Rest of South America Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 22. Rest of South America Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 23. Rest of South America Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 24. Asia Pacific Medical Sevofluran, by Country USD Million (2015-2020)
  • Table 25. Asia Pacific Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 26. Asia Pacific Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 27. Asia Pacific Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 28. China Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 29. China Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 30. China Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 31. Japan Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 32. Japan Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 33. Japan Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 34. India Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 35. India Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 36. India Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 37. South Korea Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 38. South Korea Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 39. South Korea Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 40. Taiwan Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 41. Taiwan Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 42. Taiwan Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 43. Australia Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 44. Australia Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 45. Australia Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 49. Europe Medical Sevofluran, by Country USD Million (2015-2020)
  • Table 50. Europe Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 51. Europe Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 52. Europe Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 53. Germany Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 54. Germany Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 55. Germany Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 56. France Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 57. France Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 58. France Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 59. Italy Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 60. Italy Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 61. Italy Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 62. United Kingdom Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 63. United Kingdom Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 64. United Kingdom Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 65. Netherlands Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 66. Netherlands Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 67. Netherlands Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 68. Rest of Europe Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 69. Rest of Europe Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 70. Rest of Europe Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 71. MEA Medical Sevofluran, by Country USD Million (2015-2020)
  • Table 72. MEA Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 73. MEA Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 74. MEA Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 75. Middle East Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 76. Middle East Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 77. Middle East Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 78. Africa Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 79. Africa Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 80. Africa Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 81. North America Medical Sevofluran, by Country USD Million (2015-2020)
  • Table 82. North America Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 83. North America Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 84. North America Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 85. United States Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 86. United States Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 87. United States Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 88. Canada Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 89. Canada Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 90. Canada Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 91. Mexico Medical Sevofluran, by Type USD Million (2015-2020)
  • Table 92. Mexico Medical Sevofluran, by Patient type USD Million (2015-2020)
  • Table 93. Mexico Medical Sevofluran, by Concentrations USD Million (2015-2020)
  • Table 94. Medical Sevofluran Sales: by Type(N)
  • Table 95. Medical Sevofluran Sales Generic Drug , by Region N (2015-2020)
  • Table 96. Medical Sevofluran Sales Original Drug , by Region N (2015-2020)
  • Table 97. Medical Sevofluran Sales: by Patient type(N)
  • Table 98. Medical Sevofluran Sales Children , by Region N (2015-2020)
  • Table 99. Medical Sevofluran Sales Adults , by Region N (2015-2020)
  • Table 100. Medical Sevofluran Sales: by Concentrations(N)
  • Table 101. Medical Sevofluran Sales 5% sevoflurane (Adults) , by Region N (2015-2020)
  • Table 102. Medical Sevofluran Sales 7% sevoflurane (children) , by Region N (2015-2020)
  • Table 103. Medical Sevofluran Sales Others , by Region N (2015-2020)
  • Table 104. South America Medical Sevofluran Sales, by Country N (2015-2020)
  • Table 105. South America Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 106. South America Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 107. South America Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 108. Brazil Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 109. Brazil Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 110. Brazil Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 111. Argentina Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 112. Argentina Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 113. Argentina Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 114. Rest of South America Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 115. Rest of South America Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 116. Rest of South America Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 117. Asia Pacific Medical Sevofluran Sales, by Country N (2015-2020)
  • Table 118. Asia Pacific Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 119. Asia Pacific Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 120. Asia Pacific Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 121. China Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 122. China Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 123. China Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 124. Japan Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 125. Japan Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 126. Japan Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 127. India Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 128. India Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 129. India Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 130. South Korea Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 131. South Korea Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 132. South Korea Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 133. Taiwan Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 134. Taiwan Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 135. Taiwan Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 136. Australia Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 137. Australia Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 138. Australia Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 139. Rest of Asia-Pacific Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 140. Rest of Asia-Pacific Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 141. Rest of Asia-Pacific Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 142. Europe Medical Sevofluran Sales, by Country N (2015-2020)
  • Table 143. Europe Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 144. Europe Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 145. Europe Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 146. Germany Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 147. Germany Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 148. Germany Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 149. France Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 150. France Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 151. France Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 152. Italy Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 153. Italy Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 154. Italy Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 155. United Kingdom Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 156. United Kingdom Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 157. United Kingdom Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 158. Netherlands Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 159. Netherlands Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 160. Netherlands Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 161. Rest of Europe Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 162. Rest of Europe Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 163. Rest of Europe Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 164. MEA Medical Sevofluran Sales, by Country N (2015-2020)
  • Table 165. MEA Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 166. MEA Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 167. MEA Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 168. Middle East Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 169. Middle East Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 170. Middle East Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 171. Africa Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 172. Africa Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 173. Africa Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 174. North America Medical Sevofluran Sales, by Country N (2015-2020)
  • Table 175. North America Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 176. North America Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 177. North America Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 178. United States Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 179. United States Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 180. United States Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 181. Canada Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 182. Canada Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 183. Canada Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 184. Mexico Medical Sevofluran Sales, by Type N (2015-2020)
  • Table 185. Mexico Medical Sevofluran Sales, by Patient type N (2015-2020)
  • Table 186. Mexico Medical Sevofluran Sales, by Concentrations N (2015-2020)
  • Table 187. Medical Sevofluran: by Type(USD/Units)
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Medical Sevofluran: by Type(USD Million)
  • Table 197. Medical Sevofluran Generic Drug , by Region USD Million (2021-2026)
  • Table 198. Medical Sevofluran Original Drug , by Region USD Million (2021-2026)
  • Table 199. Medical Sevofluran: by Patient type(USD Million)
  • Table 200. Medical Sevofluran Children , by Region USD Million (2021-2026)
  • Table 201. Medical Sevofluran Adults , by Region USD Million (2021-2026)
  • Table 202. Medical Sevofluran: by Concentrations(USD Million)
  • Table 203. Medical Sevofluran 5% sevoflurane (Adults) , by Region USD Million (2021-2026)
  • Table 204. Medical Sevofluran 7% sevoflurane (children) , by Region USD Million (2021-2026)
  • Table 205. Medical Sevofluran Others , by Region USD Million (2021-2026)
  • Table 206. South America Medical Sevofluran, by Country USD Million (2021-2026)
  • Table 207. South America Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 208. South America Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 209. South America Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 210. Brazil Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 211. Brazil Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 212. Brazil Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 213. Argentina Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 214. Argentina Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 215. Argentina Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 216. Rest of South America Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 217. Rest of South America Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 218. Rest of South America Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 219. Asia Pacific Medical Sevofluran, by Country USD Million (2021-2026)
  • Table 220. Asia Pacific Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 221. Asia Pacific Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 222. Asia Pacific Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 223. China Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 224. China Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 225. China Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 226. Japan Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 227. Japan Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 228. Japan Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 229. India Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 230. India Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 231. India Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 232. South Korea Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 233. South Korea Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 234. South Korea Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 235. Taiwan Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 236. Taiwan Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 237. Taiwan Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 238. Australia Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 239. Australia Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 240. Australia Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 241. Rest of Asia-Pacific Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 242. Rest of Asia-Pacific Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 243. Rest of Asia-Pacific Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 244. Europe Medical Sevofluran, by Country USD Million (2021-2026)
  • Table 245. Europe Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 246. Europe Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 247. Europe Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 248. Germany Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 249. Germany Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 250. Germany Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 251. France Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 252. France Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 253. France Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 254. Italy Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 255. Italy Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 256. Italy Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 257. United Kingdom Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 258. United Kingdom Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 259. United Kingdom Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 260. Netherlands Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 261. Netherlands Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 262. Netherlands Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 263. Rest of Europe Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 264. Rest of Europe Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 265. Rest of Europe Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 266. MEA Medical Sevofluran, by Country USD Million (2021-2026)
  • Table 267. MEA Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 268. MEA Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 269. MEA Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 270. Middle East Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 271. Middle East Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 272. Middle East Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 273. Africa Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 274. Africa Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 275. Africa Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 276. North America Medical Sevofluran, by Country USD Million (2021-2026)
  • Table 277. North America Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 278. North America Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 279. North America Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 280. United States Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 281. United States Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 282. United States Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 283. Canada Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 284. Canada Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 285. Canada Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 286. Mexico Medical Sevofluran, by Type USD Million (2021-2026)
  • Table 287. Mexico Medical Sevofluran, by Patient type USD Million (2021-2026)
  • Table 288. Mexico Medical Sevofluran, by Concentrations USD Million (2021-2026)
  • Table 289. Medical Sevofluran Sales: by Type(N)
  • Table 290. Medical Sevofluran Sales Generic Drug , by Region N (2021-2026)
  • Table 291. Medical Sevofluran Sales Original Drug , by Region N (2021-2026)
  • Table 292. Medical Sevofluran Sales: by Patient type(N)
  • Table 293. Medical Sevofluran Sales Children , by Region N (2021-2026)
  • Table 294. Medical Sevofluran Sales Adults , by Region N (2021-2026)
  • Table 295. Medical Sevofluran Sales: by Concentrations(N)
  • Table 296. Medical Sevofluran Sales 5% sevoflurane (Adults) , by Region N (2021-2026)
  • Table 297. Medical Sevofluran Sales 7% sevoflurane (children) , by Region N (2021-2026)
  • Table 298. Medical Sevofluran Sales Others , by Region N (2021-2026)
  • Table 299. South America Medical Sevofluran Sales, by Country N (2021-2026)
  • Table 300. South America Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 301. South America Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 302. South America Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 303. Brazil Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 304. Brazil Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 305. Brazil Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 306. Argentina Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 307. Argentina Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 308. Argentina Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 309. Rest of South America Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 310. Rest of South America Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 311. Rest of South America Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 312. Asia Pacific Medical Sevofluran Sales, by Country N (2021-2026)
  • Table 313. Asia Pacific Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 314. Asia Pacific Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 315. Asia Pacific Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 316. China Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 317. China Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 318. China Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 319. Japan Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 320. Japan Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 321. Japan Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 322. India Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 323. India Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 324. India Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 325. South Korea Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 326. South Korea Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 327. South Korea Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 328. Taiwan Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 329. Taiwan Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 330. Taiwan Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 331. Australia Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 332. Australia Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 333. Australia Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 334. Rest of Asia-Pacific Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 335. Rest of Asia-Pacific Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 336. Rest of Asia-Pacific Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 337. Europe Medical Sevofluran Sales, by Country N (2021-2026)
  • Table 338. Europe Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 339. Europe Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 340. Europe Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 341. Germany Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 342. Germany Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 343. Germany Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 344. France Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 345. France Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 346. France Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 347. Italy Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 348. Italy Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 349. Italy Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 350. United Kingdom Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 351. United Kingdom Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 352. United Kingdom Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 353. Netherlands Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 354. Netherlands Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 355. Netherlands Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 356. Rest of Europe Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 357. Rest of Europe Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 358. Rest of Europe Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 359. MEA Medical Sevofluran Sales, by Country N (2021-2026)
  • Table 360. MEA Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 361. MEA Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 362. MEA Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 363. Middle East Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 364. Middle East Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 365. Middle East Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 366. Africa Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 367. Africa Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 368. Africa Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 369. North America Medical Sevofluran Sales, by Country N (2021-2026)
  • Table 370. North America Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 371. North America Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 372. North America Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 373. United States Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 374. United States Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 375. United States Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 376. Canada Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 377. Canada Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 378. Canada Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 379. Mexico Medical Sevofluran Sales, by Type N (2021-2026)
  • Table 380. Mexico Medical Sevofluran Sales, by Patient type N (2021-2026)
  • Table 381. Mexico Medical Sevofluran Sales, by Concentrations N (2021-2026)
  • Table 382. Medical Sevofluran: by Type(USD/Units)
  • Table 383. Research Programs/Design for This Report
  • Table 384. Key Data Information from Secondary Sources
  • Table 385. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Medical Sevofluran: by Type USD Million (2015-2020)
  • Figure 5. Global Medical Sevofluran: by Patient type USD Million (2015-2020)
  • Figure 6. Global Medical Sevofluran: by Concentrations USD Million (2015-2020)
  • Figure 7. South America Medical Sevofluran Share (%), by Country
  • Figure 8. Asia Pacific Medical Sevofluran Share (%), by Country
  • Figure 9. Europe Medical Sevofluran Share (%), by Country
  • Figure 10. MEA Medical Sevofluran Share (%), by Country
  • Figure 11. North America Medical Sevofluran Share (%), by Country
  • Figure 12. Global Medical Sevofluran: by Type N (2015-2020)
  • Figure 13. Global Medical Sevofluran: by Patient type N (2015-2020)
  • Figure 14. Global Medical Sevofluran: by Concentrations N (2015-2020)
  • Figure 15. South America Medical Sevofluran Share (%), by Country
  • Figure 16. Asia Pacific Medical Sevofluran Share (%), by Country
  • Figure 17. Europe Medical Sevofluran Share (%), by Country
  • Figure 18. MEA Medical Sevofluran Share (%), by Country
  • Figure 19. North America Medical Sevofluran Share (%), by Country
  • Figure 20. Global Medical Sevofluran: by Type USD/Units (2015-2020)
  • Figure 21. Global Medical Sevofluran share by Players 2020 (%)
  • Figure 22. Global Medical Sevofluran share by Players (Top 3) 2020(%)
  • Figure 23. Global Medical Sevofluran share by Players (Top 5) 2020(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 27. Maruishi Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Maruishi Pharmaceutical (Japan) Revenue: by Geography 2020
  • Figure 29. Collins Ltd (Taiwan) Revenue, Net Income and Gross profit
  • Figure 30. Collins Ltd (Taiwan) Revenue: by Geography 2020
  • Figure 31. Shenzhen Mindray Bio-Medical Electronics (China) Revenue, Net Income and Gross profit
  • Figure 32. Shenzhen Mindray Bio-Medical Electronics (China) Revenue: by Geography 2020
  • Figure 33. Mylan Seiyaku (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Mylan Seiyaku (Japan) Revenue: by Geography 2020
  • Figure 35. Baxter (United States) Revenue, Net Income and Gross profit
  • Figure 36. Baxter (United States) Revenue: by Geography 2020
  • Figure 37. Jinan MingRui (China) Revenue, Net Income and Gross profit
  • Figure 38. Jinan MingRui (China) Revenue: by Geography 2020
  • Figure 39. Hikma (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. Hikma (United Kingdom) Revenue: by Geography 2020
  • Figure 41. Global Medical Sevofluran: by Type USD Million (2021-2026)
  • Figure 42. Global Medical Sevofluran: by Patient type USD Million (2021-2026)
  • Figure 43. Global Medical Sevofluran: by Concentrations USD Million (2021-2026)
  • Figure 44. South America Medical Sevofluran Share (%), by Country
  • Figure 45. Asia Pacific Medical Sevofluran Share (%), by Country
  • Figure 46. Europe Medical Sevofluran Share (%), by Country
  • Figure 47. MEA Medical Sevofluran Share (%), by Country
  • Figure 48. North America Medical Sevofluran Share (%), by Country
  • Figure 49. Global Medical Sevofluran: by Type N (2021-2026)
  • Figure 50. Global Medical Sevofluran: by Patient type N (2021-2026)
  • Figure 51. Global Medical Sevofluran: by Concentrations N (2021-2026)
  • Figure 52. South America Medical Sevofluran Share (%), by Country
  • Figure 53. Asia Pacific Medical Sevofluran Share (%), by Country
  • Figure 54. Europe Medical Sevofluran Share (%), by Country
  • Figure 55. MEA Medical Sevofluran Share (%), by Country
  • Figure 56. North America Medical Sevofluran Share (%), by Country
  • Figure 57. Global Medical Sevofluran: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Abbott Laboratories (United States)
  • Maruishi Pharmaceutical (Japan)
  • Collins Ltd (Taiwan)
  • Shenzhen Mindray Bio-Medical Electronics (China)
  • Mylan Seiyaku (Japan)
  • Baxter (United States)
  • Jinan MingRui (China)
  • Hikma (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation